C. Louvet
University of Paris
140 Papers
1.2K Citations
C. Louvet is an academic researcher from University of Paris. The author has contributed to research in topics: Oxaliplatin & Regimen. The author has an hindex of 32, co-authored 138 publications. Previous affiliations of C. Louvet include French Institute of Health and Medical Research.
Chat about Author
Papers
Place et intérêt de l'oxaliplatine dans les cancers colorectaux métastasés
C. Louvet,A. de Gramont +1 more
TL;DR: L'association oxaliplatine-5-FU module doit etre consideree comme une des alternatives les plus attractives en deuxieme ligne chez les patients presentant un cancer colorectal metastatique apres progression sous 5-FU.
5
Docetaxel (D) and oxaliplatin (DOCELOX) in advanced ovarian cancer (AOC): Preliminary safety results of a phase I-II
Christophe Tournigand,Elisabeth Carola,F. Maindrault Goebel,M. Bennamoun,M.L. Garcia,H. Gervais,N. Perez,A. Plantade,C. Louvet,A. de Gramont +9 more
TL;DR: A phase I-II study was initiated to evaluate docetaxel (D) and oxaliplatin in AOC and to evaluate the potential of these drugs in combination with chemotherapy.
4
Microsatellite instability status as a predictive marker of clinical outcome from FOLFOX adjuvant chemotherapy in stage III colon cancer.
A. Zaanan,Jean-François Fléjou,J.F. Emile,Pierre Validire,C. Louvet,Ph. Rougier,A. de Gramont,Françoise Praz,Julien Taieb +8 more
TL;DR: Adding oxaliplatin to 5-FU re-establishes a benefit of adjuvant treatment in the stage III MSI population, and a trend toward longer survival was observed for patients with MSI tumors compared with those with MSS tumors but the differences in survival were not significant.
4
LBA29Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial
Julien Edeline,F. Bonnetain,J.M. Phelip,Jérôme Watelet,Pascal Hammel,J-P. Joly,M. Benabdelghani,Laetitia Fartoux,Karine Bouhier-Leporrier,J-L. Jouve,Roger Faroux,Veronique Guerin-Meyer,Eric Assenat,J.F. Seitz,David Malka,C. Louvet,Aurélie Bertaut,Beata Juzyna,Trevor Stanbury,E. Boucher +19 more
4
Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT1 and dCK protein expression.
Raphaël Maréchal,J-B. Bachet,John R. Mackey,P. Demetter,Kathryn Graham,Anne Couvelard,Magali Svrcek,Armelle Bardier,Pascal Hammel,Alain Sauvanet,C. Louvet,François Paye,Ph. Rougier,Laurent Hannoun,T. Andre,Charles Dumontet,Carol E. Cass,Isabelle Salmon,Jean-François Emile,J.-L. Van Laethem +19 more
TL;DR: In resected pancreatic adenocarcinoma (PA), gemcitabine was shown to improve both DFS and OS, equally to 5FU.
4